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Abstract
Gene therapy was initially envisaged as a potential treatment for genetically inherited,
monogenic disorders. The applications of gene therapy have now become wider, however,
and include cardiovascular diseases, vaccination and cancers in which conventional
therapies have failed. With regard to oncology, various gene therapy approaches have been
developed. Among them, the use of genetic toxins to kill cancer cells selectively is emerging.
Two different types of genetic toxins have been developed so far: the metabolic toxins and
the dominant-negative class of toxins. This review describes these two different approaches,
and discusses their potential applications in cancer gene therapy.
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CD = cytosine deaminase; GPAT = genetic prodrug activation therapy; HSV-TK = herpes simplex virus thymidine kinase; Kcat = coefficient of
catalysis; Km = Michaelis-Menten constant.
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Introduction
The first demonstration of the use of controlled expression
of an exogenous gene encoding a toxin as a mean of killing
cancer cells was described in 1986 [1•]. In those experi-
ments, a direct suicide gene (the diphtheria toxin A chain)
was used. Extrapolated to a clinical scenario, the use of
such a potent genetic toxin (a single diphtheria toxin A chain
molecule is capable of killing a cell) would require efficient
and very reliable selective targeting of cancer cells. This tar-
geting can be achieved by targeted delivery [2] or by tran-
scriptional targeting [3]. For breast cancer gene therapy, a
few promoters have already been used to drive the expres-
sion of genetic toxins (Table 1). With current tools, however,
accurate targeting cannot be achieved. To accommodate
these safety issues, a whole branch of cancer gene therapy
has been dedicated to the design of more controllable and
specific genetic toxins. These new ‘suicide’ genes can be
classified into two groups: the metabolic suicide genes and
the dominant-negative class of suicide genes. This review
describes the rationale of these suicide systems and pre-
sents their potential applications in breast cancer therapies.
Metabolic suicide gene systems
This strategy relies upon intracellular conversion of a rela-
tively nontoxic prodrug into a toxic drug by an enzyme of
xenobiotic origin, and has been referred to as genetic
prodrug activation therapy (GPAT). Plant, fungi, bacteria
and viruses often utilize unique metabolic pathways that
are adapted to their life cycles and environments. These
metabolic routes are not used by mammalian cells. In the
case of pathogen infections, the distinctive enzymes
responsible for these functions have been the target of
prodrugs that are developed to be selectively metabolized
in infected cells, leading to their destruction. This process
is selective, because the prodrug is not toxic to healthy,
uninfected mammalian cells.http://breast-cancer-research.com/content/2/1/022
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The transfer of the genes encoding these enzymes to mam-
malian cells is sufficient to confer sensitivity to particular pro-
drugs that are metabolized by the individual enzymes. In
terms of cancer gene therapy, the process would involve tar-
geted delivery of these genes to the cancer cells, followed
by the administration of the prodrug. Compared with a more
direct approach, using a suicide gene such as the diphtheria
toxin A chain, this prodrug–enzyme system offers extra levels
of control, in terms of variation of prodrug concentration as
well as prodrug bioavailability and tissue distribution.
Examples of enzyme–prodrug systems
The most suitable enzymes are monomeric proteins,
without any requirement for glycosylation. More complex
enzymes may not be correctly folded in an ectopic envi-
ronment and, as a result, may be less efficient at convert-
ing the prodrug. This conversion should be rapid [high
coefficient of catalysis (Kcat)] and should require low con-
centrations of prodrug [low Michaelis-Menten constant
(Km)]. In addition, the prodrug should be at least two
orders of magnitude less toxic than the active anabolite.
Several enzyme–prodrug systems have been reported
(Table 2), and some of these are described below.
Herpes simplex virus thymidine kinase
Ganciclovir and acyclovir are guanosine analogues that
are poorly metabolized by mammalian cellular thymidine
kinases. By contrast, herpes simplex virus thymidine
kinase (HSV-TK) metabolizes these prodrugs very effi-
ciently to their monophosphate forms (the rate-limiting
step). In turn, the monophosphate form is metabolized to
ganciclovir diphosphate and triphosphate by cellular
enzymes. The triphosphate form of the prodrug inhibits a-
DNA polymerase [4] and is incorporated into DNA, result-
ing in chain termination during replication [5]. This
molecular mechanism of action implies that this
enzyme–prodrug system will only be effective for actively
dividing cells and should not affect quiescent cells within
a tumour. This view has been challenged by the observa-
tion that this system induces significant cell death in
tissues with low mitotic indices, however [6]. In these
cases, the mechanism of action is unclear and seems to
involve a p53-independent apoptosis [6]. Very recently, a
library of mutants of HSV-TK was created, from which a
more effective form of the enzyme (mutant 30) was
described [7•]. This type of approach could be applied to
improve the characteristics of other enzymes.
Cytosine deaminase
Cytosine deaminase (CD) is an enzyme of bacterial or
fungal origin that is activated in response to nutritional
stress, deaminating cytosine to uracil. This enzyme
became a target for therapy and the prodrug 5-fluorocyto-
sine was selected. 5-Fluorocytosine is metabolized to
Table 1
Promoter constructs that have been exploited for breast
carcinoma gene therapy
Promoter construct Reference
DF3/MUC1 promoter [37]
ErbB-2 promoter [3,27••,38]
ErbB-2 promoter/MUC1 enhancer [39]
Table 2
Enzyme-prodrug systems under investigation for genetic prodrug activation therapy applications
Enzyme Prodrug Cytotoxic product
Herpes simplex virus thymidine kinase Ganciclovir Ganciclovir triphosphate
Cytosine deaminase 5-Fluorocytosine 5-Fluorouracil
Varicella zoster virus thymidine kinase 6-Methoxypurine arabinose Adenine arabinonucleoside triphosphate
Nitroreductase CB1954 5-Aziridinyl-4-hydroxylamino-2-nitrobenzamide
Cytochrome p450 Cyclophosphamide Acrolein and phosphoramide mustard
Thymidine phosphorylase 5¢-Deoxy-5-fluorouridine 5-Fluorouracil
Purine nucleoside phosphorylase 6-Methylpurine-deoxyriboside 6-Methylpurine
Alkaline phosphatase Etoposide phosphate Etoposide
Carboxypeptidase A Methotrexate-alanine Methotrexate
Carboxypeptidase G2 Benzoic acid mustard-glucuronide Benzoic acid mustard
Linamarase Linamarin Cyanide
Xanthine oxidase Xanthine Oxygen radicals
b-Lactamase Cephalosporin-mustard-carbamate Nitrogen mustardBreast Cancer Research    Vol 2 No 1 Vassaux and Lemoine
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5-fluorouracil by CD. Further metabolism of 5-fluorouracil
to 5-fluorouridine-5¢-triphosphate and 5-fluoro-2¢-deoxyuri-
dine-5¢-monophosphate results in cell death by affecting
RNA and DNA synthesis. The cytotoxic action of CD/5-
fluorocytosine requires the proliferation of the target cell.
Moreover, 5-fluorouracil is used as a single agent in a
limited number of cancers (gastrointestinal tract, for
example). Potential problems have been associated with
the use of 5-fluorouracil, however, such as the high doses
necessary to achieve cytotoxicity and resistance [8,9].
Nitroreductase
Nitroreductase is a monomeric enzyme that converts non-
toxic monofunctional alkylating agents to their difunctional
forms. The products of these reactions are four orders of
magnitude more toxic than the substrates [10].
Escherichia coli nitroreductase has been used to metabo-
lize the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide to
5-(aziridin-1-yl)-4-(hydroxyamino)-2-nitrobenzamide, in the
presence of cellular nicotinamide adenine dinucleotide,
reduced form, or nicotinamide adenine dinucleotide
phosphate, reduced form, acting as a reductant. The
metabolized prodrug is then acetylated to 5-(aziridin-1-yl)-
4-(acetylamino)-2-nitrobenzamide, which is capable of
cross-linking cellular DNA, resulting in apoptosis. This
system offers a large number of potential prodrugs that
may be optimized. The prodrug currently used in conjunc-
tion with nitroreductase is CB1954 [11]. This system
offers an advantage over HSV-TK and CD, in that it does
not require cell proliferation to induce cell death.
Linamarase
Linamarase is a plant gene that hydrolyzes the cyanogenic
glucoside substrate linamarin into glucose, acetone and
cyanide. To date, a single study [12] has described the use
of this enzyme for GPAT applications, but the originality of
this system resides in the fact that the toxic component
resulting from the conversion of the prodrug is a gas
(cyanide) that can freely diffuse into the adjacent cells,
inducing a strong bystander effect. Using this system, the
eradication of very large intracerebral gliomas was reported
in an animal model [12]. Furthermore, no appreciable toxic
effects were observed. Further studies will be necessary to
assess the real potential of this GPAT strategy.
Bystander effect
Antitumour gene therapy using GPAT strategies should, in
theory, be limited to the cells that have been transduced
with the suicide genes. Many investigators, however, have
reported the induction of cell death in untransduced
tumour cells. This phenomenon, referred to as the
‘bystander effect’, renders GPAT unexpectedly more effi-
cient than initially predicted. For most of the suicide
genes/prodrugs, the molecular mechanisms of this
bystander effect have now been characterized, and can be
divided into chemical and immunological bystander
effects.  In vivo, both of these effects may be observed
within the same experiment, but with different kinetics.
Chemical bystander effect
One of the first observations of this phenomenon was
reported by Culver et al [13]. In these experiments, rat
glioma cells were transduced with a replication-deficient
retrovirus carrying the HSV-TK gene. Although only
10–70% of the tumour cells were transduced, very signifi-
cant or complete tumour ablation was observed. Another
study [14], with mixed tumour experiments, reported that
10% of HSV-TK-positive cells were sufficient in certain
cases to observe tumour regression after treatment with
ganciclovir [14]. A very elegant study [15] demonstrated
that this bystander effect was the result of a metabolic
cooperation, in which molecules of low molecular weight
passed from one cell to another through gap junctions. In
those experiments, the same cell line was transduced with
either HSV-TK or the LacZ gene. When these cells were
cocultured at low density, in which the majority of the cells
were not in contact with each other, only the HSV-TK-
expressing cells died. When the same experiment was
repeated in conditions in which the cells were in contact,
both cell lines were killed by the action of ganciclovir.
These studies strongly suggested that phosphorylated
ganciclovir may enter adjacent cells via the gap junction
and cause cell death. Another study [16] attributed this
bystander effect to the phagocytosis of apoptotic vesicles
containing HSV-TK and metabolized ganciclovir, derived
from dying cells.
Similar bystander effects were reported with other suicide
genes/prodrugs, but the mechanism of toxicity varies
among the different agents. For example, it has been
shown [17] that 5-fluorouracil can diffuse to nearby
tumour cells and pass through the cell membrane. A cell
permeable metabolite is also responsible for the bystander
effect observed with nitroreductase/CB1954 [18]. In the
case of linamarase/linamarin, the cyanide gas produced
freely diffuses from one cell to another [12].
Immunological bystander effect
The introduction of the HSV-TK gene into tumour cells,
followed by the administration of ganciclovir in vivo, has
also been demonstrated, in some cases, to induce the
generation of a T-cell dependent antitumour immunity
[19,20,21••]. For example, Kianmanesh et al [21••] demon-
strated the existence of a ‘distant’ bystander effect;
HSV-TK-positive or -negative malignant cells were seeded
simultaneously in different rat liver lobes, in such a manner
that there was no contact between the resulting tumours.
After treatment of the rats with ganciclovir, both HSV-TK-
positive and HSV-TK-negative tumours regressed and
showed infiltration with macrophages and T lymphocytes.
Protective immunity to the wild-type tumour was also
induced when CD/5-fluorocytosine was used [22,23].An important parameter that influences this immunological
bystander effect is the way in which tumour cell death is
induced. Apoptosis is usually associated with cell death in
normal developmental processes [24], whereas cell death
by a nonapoptotic pathway can be seen as a ‘danger’
signal (in viral-induced tissue lysis for example), and there-
fore is more likely to stimulate a immune response. HSV-
TK/ganciclovir-mediated tumour killing can occur via
apoptotic or nonapoptotic mechanisms, and experimen-
tally the mechanism of HSV-TK-induced cell death can be
diverted from apoptosis to nonapoptosis by manipulating
intracellular levels of Bcl-2 [25••]. Using this system,
Melcher  et al [25••] demonstrated that HSV-TK-induced
cell death by a nonapoptotic mechanism was associated
with much higher immunogenicity than when tumour death
was induced via an apoptotic pathway.
Intriguingly, a ‘distant’ bystander effect was reported [26]
in a plasmacytoma model, when human tumour cells were
transferred to severe combined immunodeficient mice. In
these mice, a DNA-dependent protein kinase involved in
immunoreceptor gene recombination is deficient. This
genetic defect causes a complete absence of functional T
as well as B lymphocytes. That study suggested that
inflammatory cells or natural killer cells might participate in
the distant bystander effect observed in immunocompe-
tent animals.
Genetic prodrug activation therapy clinical trial for breast
cancer
To date, only one phase I clinical trial using GPAT as a
potential treatment for breast cancer has been described
[27••]. The purpose of the trial was to test the safety and
efficacy of tumour-specific expression of the CD gene
driven by the erbB-2 promoter. The erbB-2 oncogene is
overexpressed in 20% of breast carcinomas and is associ-
ated with reduced relapse-free and overall patient survival
[28]. Twelve breast cancer patients received the transcrip-
tionally targeted CD gene using direct, intratumoural injec-
tion of plasmid DNA, combined with systemic
administration of the prodrug. The approach was shown to
be safe and resulted in targeted expression of the CD
gene in 90% of cases. Significant levels of expression of
the suicide gene were detected and this expression was
restricted to erbB-2-positive tumour cells. No significant,
macroscopically observable tumor regression was
reported, however. As a proof of principle, that study
demonstrated the feasibility of exploiting transcriptional
targeting to drive the expression of suicide genes.
Dominant-negative class of suicide genes
Many studies have been dedicated to the identification of
the genetic defects that are associated with the formation
and progression of tumours. Among these genetic abnor-
malities, activating mutations in the ras oncogenes con-
tribute to around 30% of human malignancies [29]. In
laboratory experiments, constitutive activation of the Ras
signalling pathway has been identified as essential for cel-
lular transformation [30••]. Although Ras has clearly been
implicated as an inducer of apoptosis in some cellular
systems [31•], its role in carcinomas and myeloid cells is
clearly to protect the transformed cells from apoptosis by
inducing, in these cells, a strong survival signal [31•]. This
survival pathway triggered by Ras activation has been
partly characterized and encompasses phosphatidyl inosi-
tol-3 kinase [32] and the protein serine/threonine kinase
akt, also known as the protein kinase B [33]. These find-
ings suggest that disruption of Ras function may be an
effective approach in the treatment of carcinomas.
The elucidation of the Ras signalling pathway was made
possible partly because of ‘dominant-negative’ proteins.
These proteins are mutated versions of natural proteins
and act as terminators of signalling pathways. For
example, the dominant-negative Ras N116Y was created
from the v-H-ras oncogene by substitution of tyrosine for
asparagine at codon 116 [34]. This mutation leads to the
destruction of the guanosine triphosphate-binding site and
results in a catalytically inactive enzyme that can neverthe-
less bind to downstream elements of the signalling
pathway. The dominant-negative will then compete with
the normal Ras and may totally block the pathway. Using
this approach, it was demonstrated that transfection of
Ras N116Y to various human cell lines of malignant origin
resulted in growth inhibition in vitro [35]. These results
were expanded in vivo, when two oesophageal cell lines,
containing a mutant Ras or a wild-type Ras, were used to
seed tumours in nude mice [36•]. The animals then
received a treatment that consisted of repeated injections
of adenovirus carrying the dominant-negative Ras N116Y
driven by the cytomegalovirus promoter. The treatment
significantly reduced the growth of both cell lines in vivo,
without any noticeable adverse effects. That study is, to
our knowledge, unique thus far as it demonstrates the clin-
ical potential of this strategy. Moreover, the elucidation of
the complete Ras signalling pathway could give rise to a
growing number of dominant-negative genes that could be
used in conjunction to block the survival pathway.
Conclusion
Since the first experimental demonstration showing effi-
cient killing of cells by a transfected gene encoding diph-
theria toxin A chain, a variety of new genetic toxins have
been designed and tested in preclinical studies. The first
clinical trial of GPAT for breast cancer has just been com-
pleted, and demonstrated the safety and feasibility of the
strategy. The long-term success of GPAT systems for clin-
ical treatment of cancer will rely on the development of
efficient and targeted gene therapy systems, however.
This targeting can be achieved in two ways: targeted
delivery, in which the gene medicine will be selectively
delivered to the tumour cells; and transcriptional targeting,
http://breast-cancer-research.com/content/2/1/022
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which uses promoters that will be active only in tumour
cells. Ideally, a combination of both targeting systems will
be used.
As an alternative to GPAT, exploitation of the knowledge
accumulated on mechanisms adopted by cancer cells to
evade programmed cell death could produce genetic
toxins such as dominant-negative mutants of the Ras sig-
nalling pathway that are more specific to cancer cells and
do not need such sophisticated targeting systems. This
type of approach is only just being tested, and safety
issues remain to be addressed.
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